BioSpace News Archive

Oxurion NV a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced that it will participate in two upcoming investor conferences.

Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, will report its financial results for the quarterly period ended September 30, 2022 after the close of the market on Thursday, November 3, 2022.

More than 700 guests, including employees, community members, elected officials and SC Governor Henry McMaster, celebrated the grand opening of Nutramax Laboratories’ 200,000 square foot expansion.

Annexon, Inc. announced that it has granted equity inducement awards to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. EST on Monday, November 14, 2022 to report its financial results for the second quarter ended September 30, 2022 and provide a corporate update.

Berkeley Lights, Inc., a leader in digital cell biology, announced that the Company will be reporting financial results for the third quarter 2022 after market on Tuesday, November 8, 2022.

LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, will issue its third quarter earnings release after the market closes on Tuesday, November 8, 2022.

Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2022 financial results will be released on Tuesday, November 1, 2022 after the markets close.

Veracyte, Inc. (Nasdaq: VCYT) today announced that two abstracts highlighting the clinical value of the company’s Envisia Genomic Classifier and Percepta Nasal Swab tests in interstitial lung disease (ILD) and lung cancer, respectively, were presented as posters today at the American College of Chest Physicians (CHEST) Annual Meeting 2022.

CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release third quarter 2022 financial and operating results after market close on Tuesday, November 1st, 2022.